Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD1 | P21728 | 2/20 | 0.31 |
| ▸ | DRD4 | P21917 | 2/20 | 0.31 |
| ▸ | DRD5 | P21918 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16108389 | 0.84 | DRD2 (0.31) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL133214 | 0.82 | DRD2 (0.30) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL14635497 | 0.82 | — | — | |
| SCHEMBL2679836 | 0.82 | — | — | |
| SCHEMBL319659 | 0.81 | DRD2 (0.34) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL9934093 | 0.79 | — | — | |
| SCHEMBL318316 | 0.79 | — | — | |
| SCHEMBL2679740 | 0.78 | — | — | |
| SCHEMBL305737 | 0.78 | DRD2 (0.31) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL3615951 | 0.77 | EPHX1 (0.31) | DRD2DRD1DRD4DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015362-A1 | Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine | TEVA PHARMACEUTICALS USA, INC. | 2008-01-17 | — | — | US | claimed |
| US-20070238883-A1 | Process for the preparation of(s)-(+)-N,N-dimethyl-3-(1-Naphthalenyloxy)-3-(2-Thienyl)propanamine, A duloxetine intermediate | TEVA PHARMACEUTICALS USA, INC. | 2007-10-11 | — | — | US | claimed |
| EP-2406795-B1 | ELECTROLYTE COMPOSITION | RISE ACREO AB (SE) | 2018-04-25 | — | — | EP | disclosed |
| US-20120126931-A1 | ELECTROLYTE COMPOSITION | SERICOL LIMITED (GB) | 2012-05-24 | — | — | US | disclosed |
| US-20080015362-A1 | Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine | TEVA PHARMACEUTICALS USA, INC. | 2008-01-17 | — | — | US | disclosed |
| US-20070238883-A1 | Process for the preparation of(s)-(+)-N,N-dimethyl-3-(1-Naphthalenyloxy)-3-(2-Thienyl)propanamine, A duloxetine intermediate | TEVA PHARMACEUTICALS USA, INC. | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015362-A1 | Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine | HTR3A, PNMT, TPH1 | DRD2 78/4885DRD1 84/4885DRD4 65/4885 |
| US-20070238883-A1 | Process for the preparation of(s)-(+)-N,N-dimethyl-3-(1-Naphthalenyloxy)-3-(2-Thienyl)propanamine, A duloxetine intermediate | DNTT, NES, PNMT | DRD2 145/4885DRD1 174/4885DRD4 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.